绝经前后子宫内膜腺癌ER和PR及C-erbB2表达状况的比较  

Comparison between expression of ER, PR, and C-erbB2 in patients with premenopausal or postmenopausal adenocarcinoma endometrium

作　　者：焦思萌[1] 孔为民[1] 李霞[1] 姜艳[1] 王晨[1] 张卫华[1] 

机构地区：[1]首都医科大学附属北京妇产医院妇瘤科,北京100006

出　　处：《西南国防医药》2015年第11期1203-1206,共4页Medical Journal of National Defending Forces in Southwest China

摘　　要：目的比较分析绝经前后子宫内膜腺癌患者雌激素受体（ER）、孕激素受体（PR）及C-erb B2表达状况。方法检测我院2002年1月～2003年12月收治的40例绝经前子宫内膜腺癌患者与95例同期收治的绝经后子宫内膜腺癌患者标本的ER、PR及C-erb B2表达状况。结果绝经前组ER阳性表达率为77.5%,绝经后为58.9%;绝经前组PR阳性表达率为75.0%,绝经后组为55.8%;C-erb B2绝经前组阳性表达率为42.5%,绝经后组为64.2%,两组间差异均有统计学意义（P〈0.05）。结论绝经前发生的子宫内膜腺癌ER和PR表达率高于绝经后患者,而C-erb B2表达前者低于后者,提示绝经前发生的子宫内膜腺癌可能有更好的预后。Objective To make comparison between the expression of ER, PR, and C-erbB2 in patients with premenopausal or postmenopausal adenocareinoma endometrium. Methods Detection was made in the expression of ER, PR, and C-erbB2 in the samples of 40 cases with premenopausal adenocarcinoma endometrium who were hospitalized in our hospital between January 2002 and December 2003 and 95 cases with postmenopausal adenocarcinoma endometrium who were hospitalized at the same time. Results The positive expression rate of ER and PR in the premenopausal adenocarcinoma endometrium group was 77.5%, and that in the postmenopausal adenocarcinoma endometrium group was 58.9%. The positive expression rate of PR in the premenopausal group was 75.0%, and that in the postmenopausal was 55.8%. The positive expression rates of C-erbB2 in the two groups were 42.5% and 64.2%, respectively, and the differences between the groups were significant （P 〈 0.05）. Conclusion The positive expression rates of ER and PR in patients with premenopausal adenocarcinoma endometrium are higher than those in patients with postmenopausal adenocarcinoma endometrium, while the expression rate of C-erbB2 in the former group is lower than that in the latter one, which indicates that patients with premenopausal adenocarcinoma endometrium may have better prognosis.

关 键 词：子宫内膜 腺癌 绝经前 绝经后 雌激素 孕激素 受体 

分 类 号：R737.33[医药卫生—肿瘤]